Duality Advisers LP Buys 7,682 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Duality Advisers LP raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 81.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,112 shares of the biopharmaceutical company’s stock after buying an additional 7,682 shares during the period. Duality Advisers LP’s holdings in Alnylam Pharmaceuticals were worth $3,275,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Wellington Management Group LLP increased its stake in shares of Alnylam Pharmaceuticals by 6.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after purchasing an additional 364,021 shares during the last quarter. abrdn plc grew its stake in Alnylam Pharmaceuticals by 910.7% in the 4th quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock valued at $44,544,000 after buying an additional 209,691 shares during the last quarter. Royal London Asset Management Ltd. grew its stake in Alnylam Pharmaceuticals by 86.7% in the 3rd quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock valued at $54,303,000 after buying an additional 142,357 shares during the last quarter. Federated Hermes Inc. acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $26,250,000. Finally, TD Asset Management Inc boosted its holdings in Alnylam Pharmaceuticals by 38.0% in the 3rd quarter. TD Asset Management Inc now owns 495,364 shares of the biopharmaceutical company’s stock valued at $87,729,000 after purchasing an additional 136,283 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 0.0 %

Shares of ALNY traded up $0.01 during mid-day trading on Monday, reaching $144.42. The company’s stock had a trading volume of 74,515 shares, compared to its average volume of 787,793. Alnylam Pharmaceuticals, Inc. has a 52 week low of $143.50 and a 52 week high of $218.88. The company’s fifty day moving average price is $151.56 and its two-hundred day moving average price is $166.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. During the same period in the previous year, the firm earned ($1.68) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ALNY. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. Morgan Stanley decreased their price target on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 13th. Wells Fargo & Company decreased their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a research report on Friday, February 16th. Citigroup cut their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Nine analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $216.12.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.